RAD50 Hypomorphism as Basis for Response to Chemotherapy

The MRE11 complex: starting from the ends

T. Stracker, J. Petrini. (2011). Nature Reviews Molecular Cell Biology. Cited 724 times. https://doi.org/10.1038/nrm3047

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

G. Iyer, Aphrothiti J. Hanrahan, M. Milowsky, et al.. (2012). Science. Cited 687 times. https://doi.org/10.1126/science.1226344

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

G. Iyer, Aphrothiti J. Hanrahan, M. Milowsky, et al.. (2012). Science. Cited 687 times. https://doi.org/10.1126/science.1226344

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

N. Wagle, M. Berger, Matthew J. Davis, et al.. (2012). Cancer discovery. Cited 491 times. https://doi.org/10.1158/2159-8290.CD-11-0184

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

S. Zabludoff, C. Deng, M. Grondine, et al.. (2008). Molecular Cancer Therapeutics. Cited 392 times. https://doi.org/10.1158/1535-7163.MCT-08-0492

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

G. Iyer, H. Al-Ahmadie, N. Schultz, et al.. (2013). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 290 times. https://doi.org/10.1200/JCO.2012.46.5740